SEC 13F Intelligence

Managers / Q2 2025 · view latest →

NVP Associates, LLC

CIK 0001545692 · 1300 EL CAMINO REAL, SUITE 200, MENLO PARK, CA, 94025 · 650-321-8000

Reported Value
$184M
Q2 2025
Positions
7
Filings on Record
14
2019–present window
Filed
Aug 14, 2025
original filing

Summary

Nvp Associates, LLC reported $184M in U.S.-listed holdings across 7 positions for Q2 2025.

The portfolio is heavily concentrated: DAVE alone accounts for 33.9% of reported value.

Compared with Q1 2025, the fund opened 1 new position and exited 0.

Portfolio Metrics

Turnover
+1.8%
vs prior filed quarter
Largest Position
+33.9%
Dave

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $102MQ4 ’22Q1 ’23: $87MQ2 ’23: $115MQ2 ’23Q3 ’23: $112MQ4 ’23: $112MQ4 ’23Q1 ’24: $126MQ2 ’24: $91MQ2 ’24Q3 ’24: $176MQ4 ’24: $187MQ4 ’24Q1 ’25: $112MQ2 ’25: $184MQ2 ’25Q3 ’25: $166MQ4 ’25: $255MQ4 ’25Q1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 100.0%
  • Common Stock · 100.0% · $184M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
OMDAOMADA HEALTH INCNEW+2.53M2.53M+$46M$46M
DAVEDAVE INCTRIMMED350.0K232.7K+$14M$62M
MBXMBX BIOSCIENCES INCHELD+02.14M+$9M$24M
ZBIOZENAS BIOPHARMA INCHELD+01.84M+$3M$18M
TALKTALKSPACE INCHELD+09.80M+$2M$27M
OPENOPENDOOR TECHNOLOGIES INCHELD+04.19M$2M$2M
GROVGROVE COLLABORATIVE HOLD INCHELD+03.23M$645,019$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2025

7 positions
#IssuerClass% PortfolioValueShares
1DAVEDAVE INChistory →CLASS A COM NEW33.91%$62M232.7K
2OMDAOMADA HEALTH INChistory →COM25.15%$46M2.53M
3TALKTALKSPACE INChistory →COM14.80%$27M9.80M
4MBXMBX BIOSCIENCES INChistory →COM13.24%$24M2.14M
5ZBIOZENAS BIOPHARMA INChistory →COM9.67%$18M1.84M
6GROVGROVE COLLABORATIVE HOLD INChistory →COM CL A2.01%$4M3.23M
7OPENOPENDOOR TECHNOLOGIES INChistory →COM1.21%$2M4.19M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M5May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$255M6Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$166M5Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$184M7Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$112M6May 12, 202513F-HRchanges · EDGAR ↗
Q4 2024$187M7Feb 10, 202513F-HRchanges · EDGAR ↗
Q3 2024$176M8Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$91M6Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$126M6May 10, 202413F-HRchanges · EDGAR ↗
Q4 2023$112M6Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$112M8Nov 8, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M9Aug 1, 202313F-HRchanges · EDGAR ↗
Q1 2023$87M8May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$102M8Feb 14, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.